Glucocorticoid-induced hyperglycemia;Hiperglucemia inducida por glucocorticoides

Seminarios de la Fundacion Espanola de Reumatologia

Volumn 12, Issue 3, 2011, Pages 83-90

  Saigi Ullastre, Ignasi ^a   Perez Perez, Antonio ^b  

^a Unidad de Endocrinología y Nutrición   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Diagnosis; Glucocorticoids; Hyperglycemia; Steroid diabetes; Treatment

Indexed keywords

GLUCOCORTICOID;

CORTICOSTEROID THERAPY; DRUG USE; GLUCOCORTICOID INDUCED HYPERGLYCEMIA; HUMAN; HYPERGLYCEMIA; SHORT SURVEY;

EID: 79961039243     PISSN: 15773566     EISSN: 19883099     Source Type: Journal    
DOI: 10.1016/j.semreu.2011.04.004     Document Type: Short Survey

References (36)

1. Choi H.K., Seeger J.D. Glucocorticoid use and serum lipid levels in US adults: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 15:528-535.
2. Conn J.W., Fajans S.S. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism 1956, 52:114-127.
3. Owen O.E., Cahill G.F. Metabolic effects of exogenous glucocorticoids in fasted man. J Clin Invest 1973, 52:2596-2605.
4. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994, 236:619-632.
5. Blackburn D., Hux J., Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002, 17:717-720.
6. Gulliford M.C., Charlton J., Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006, 29:2728-2729.
7. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., Avorn J. Glucocorticoids and risk for initiation of hypoglycaemic therapy. Arch Intern Med 1994, 154:97-101.
8. Arner P., Gunnarsson R., Blomdahl S., Groth C.G. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983, 6:23-25.
9. Panthakalam S., Bhatnagar D., Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004, 49:139-141.
10. Habib G.S., Abu-Ahmad R. Lack of effect of corticosteroid injection at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol 2007, 26:566-568.
11. Habib G.S. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009, 28:749-756.
12. Casey J.I. Host defense abnormalities in diabetic patients. Diabetis Mellitus 1981, 5:219-223. Bowie: Robert J. Brady Company.
13. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
14. Position statement: standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl1):S11-61. American Diabetes Association.
15. Lipshutz A.K., Gropper M.A. Perioperative glycemic control: an evidence-based review. Anesthesiology 2009, 110:408-421.
16. Campbell K.B., Braithwaite S.S. Hospital management of hyperglycemia. Clin Diabetes 2004, 22:81-88.
17. Hirsch I.B., Paauw D.S. Diabetes management in special situations. Endocrinol Metab Clin North Am 1997, 26:631-645.
18. Baithwaite S.S. Inpatient insulin therapy. Curr Opin Endocrinol Diabetes Obes 2008, 15:159-166.
19. Pérez Pérez A., Conthe Gutiérrez P., Aguilar Diosdado M., Bertomeu Martínez V., Galdos Anuncibay P., García de Casasola G., et al. Hospital management of hyperglycemia. Med Clin (Barc) 2009, 132:465-475.
20. Clore J.N., Thurby-Hay N. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009, 15:469-474.
21. Saigí I., Pérez A. Management of glucocorticoid induced hyperglycemia. Rev Clin Esp 2010, 210:397-403.
22. Faul J., Wilson S.R., Chu J.W., Canfield J., Kuschner W.G. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 2009, 7:14-20.
23. McMahon M., Gerich J., Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988, 4:17-30.
24. Midvedt K., Hjelmesaeth J., Hartman A., Lund K., Paulsen D., Egeland T., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004, 15:3233-3239.
25. Matsumoto K., Yamasaki H., Akazawa S., Sakamaki H., Ishibashi M., Abiru N., et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996, 81:2621-2626.
26. Ranta F., Avram D., Berchtold S., Dufer M., Drews G., Lang F., et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006, 55:1380-1390.
27. Magee M.H., Blum R.A., Lates C.D., Jusko W.J. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001, 41:1180-1194.
28. Gustavson S.M., Sandoval D.A., Ertl A.C., Bao S., Raj S.R., Davis S.N. Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab 2008, 294:E506-E512.
29. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
30. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
31. Van Raalte D.H., Van Genugten R.E., Linssen M., Ouwens D.M., Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011, 34:412-417.
32. Campbell P.J., Gerich J.E. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for adverse effect of obesity. J Clin Endocrinol Metab 1990, 70:1114-1118.
33. Riddle M., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086. Insulin Glargine 4002 Study Investigators.
34. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
35. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007; 7:1506-1514.[correcciones en Am J Transplant. 2008; 8:908 y Am J Transplant. 2008; 8:1].
36. Redmon J.B., Olson lK, Armstrong M.B., Greene M.J., Robertson R.P. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996, 98:2786-2793.